- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07598721
Ambient AI Clinical Trial
Evaluation of Abridge Ambient AI Technology Regarding Provider Burnout and Patient Satisfaction With the Clinical Encounter
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98195
- University of Washington Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Provider is an employee of the University of Washington Medicine.
- Clinical specialty of primary care, oncology, or urology.
- Clinical full-time equivalent (FTE) of 0.2 or greater (provider must have an outpatient clinic of at least 20% of an FTE).
- Provider is a physician or an advanced practice provider.
Exclusion Criteria:
- Trainees (e.g., medical students, residents, or fellows)
- Provider does not have access to a mobile device that is compatible with the ambient AI scribe service (e.g., Android mobile phone).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Ambient AI scribe users
Participants in this arm will utilize the ambient AI scribe tools from Abridge.
They will otherwise continue their usual clinical activities, including providing care with trainees (e.g., medical students, residents) and multiple family members in the room.
The tool will be used exclusively in the outpatient clinical setting and only when the participant is present.
The ambient AI scribe tool integrates into the electronic health record (EHR), and the EHR's mobile app is used to collect the recording on a mobile device.
The ambient AI scribe tool is transcriptional and does not provide clinical decision support.
|
Ambient artificial intelligence (AI) scribes are a clinical documentation tool that uses automated speech recognition and large-scale language models to capture and transcribe synchronous patient-provider encounters in real time. Clinicians then review, edit, and authorize the AI-generated text before finalizing the chart, ensuring necessary human oversight and medical accuracy. In this study, participants used Ambient AI scribes on mobile devices for the recordings. The ambient AI scribe will be available for the provider to use in the outpatient setting. They were not required to use the Ambient AI scribe, but could choose whether to use it and with which patients. Consent to use the device was documented for all patient encounters.
Altri nomi:
|
|
Nessun intervento: Routine patient care (no AI scribe)
These participants were not provided with the ambient AI scribe application on their mobile device.
They still had access to documentation with dictation or existing scribe services (non-AI).
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Professional Fulfillment Index (PFI)
Lasso di tempo: Surveyed at enrollment (day 0 of pilot), midpoint (day 75), and end of pilot (day 150)
|
Change in professional fulfillment and burnout, measured using the Professional Fulfillment Index (PFI), a validated 16-item self-report questionnaire.
The instrument comprises three subscales: Professional Fulfillment (6 items), Work Exhaustion (4 items), and Interpersonal Disengagement (6 items).
Items are rated on a 5-point Likert scale (0 = "Not at all true" / "Not at all" to 4 = "Completely true" / "Extremely").
Subscale scores are calculated as the mean of constituent items.
Unit of measure: mean subscale score (range 0-4) and overall burnout score (mean of Work Exhaustion and Interpersonal Disengagement subscales, range 0-4).
|
Surveyed at enrollment (day 0 of pilot), midpoint (day 75), and end of pilot (day 150)
|
|
Mean Score on NASA Task Load Index (NASA-TLX)
Lasso di tempo: Surveyed at enrollment (day 0 of pilot), midpoint (day 75), and end of pilot (day 150)
|
Change in perceived workload, measured using the NASA Task Load Index (NASA-TLX), a validated multidimensional self-report questionnaire.
The instrument comprises six subscales: Mental Demand, Physical Demand, Temporal Demand, Performance, Effort, and Frustration.
Each subscale is rated on a 0-100 scale in 5-point increments.
Unit of measure: subscale score (range 0-100) and overall workload score, calculated as the unweighted mean of the six subscales (range 0-100).
Higher scores indicate greater perceived task workload associated with clinical documentation.
|
Surveyed at enrollment (day 0 of pilot), midpoint (day 75), and end of pilot (day 150)
|
|
Ambient AI scribe utilization rate (%)
Lasso di tempo: Through study completion, up to 150 days after the start of the pilot.
|
Percentage of clinical encounters in which the provider used the Abridge ambient AI scribe, measured using Abridge platform usage logs cross-referenced with electronic health record (EHR) encounter data.
Unit of measure: utilization rate, calculated as (number of encounters in which Abridge was used divided by the total number of clinical encounters during the same period).
This fraction is then represented as a percentage (range 0-100%) and aggregated monthly by provider.
|
Through study completion, up to 150 days after the start of the pilot.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time Spent in the Electronic Health Record on Clinical Note Documentation (Minutes)
Lasso di tempo: Through study completion, up to 150 days after the start of the pilot.
|
Time spent by the provider in the electronic health record on clinical note documentation activities, measured using EHR audit log data (e.g., Epic Signal Provider Efficiency Profile).
Unit of measure: minutes per scheduled clinic day on note documentation, normalized to clinical workload (clinical Full-Time Equivalent), and aggregated in 4-week windows per provider.
No patient information will be collected for this outcome measure.
|
Through study completion, up to 150 days after the start of the pilot.
|
|
Time spent in the electronic health record outside of working hours
Lasso di tempo: Through study completion, up to 150 days after the start of the pilot.
|
Time spent by the provider in the electronic health record outside of scheduled clinic/working hours (commonly referred to as "work outside of work" or "pajama time"), measured using EHR audit log data (e.g., Epic Signal Provider Efficiency Profile).
Unit of measure: minutes per scheduled clinic day spent in the EHR outside of working hours, normalized to clinical workload and aggregated in 4-week windows per provider.
No patient information will be collected for this outcome measure.
|
Through study completion, up to 150 days after the start of the pilot.
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Christopher W Lewis, MD, MS, University of Washington
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- STUDY00022081
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Periodo di condivisione IPD
Criteri di accesso alla condivisione IPD
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .